Comparative Pharmacology
Head-to-head clinical analysis: CLARITHROMYCIN versus E E S 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITHROMYCIN versus E E S 200.
CLARITHROMYCIN vs E.E.S. 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the 23S rRNA component, blocking peptide chain elongation and exerting bacteriostatic or bactericidal effects depending on concentration and organism.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
250-500 mg orally twice daily for 7-14 days; for MAC infection: 500 mg twice daily.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in adults with normal renal function; prolonged to 8-12 hours in moderate to severe renal impairment; clinical context: allows twice-daily dosing; active metabolite (14-hydroxyclarithromycin) half-life similar.
Clinical Note
moderateClarithromycin + Levofloxacin
"Clarithromycin may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateClarithromycin + Norfloxacin
"Clarithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateClarithromycin + Gemifloxacin
"Clarithromycin may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateClarithromycin + Haloperidol
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Renal: approximately 30-40% unchanged; biliary/fecal: approximately 40-50% as metabolites; total renal clearance accounts for about 30-40% of dose; hepatic metabolism contributes to elimination; dose adjustment required in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic
"Clarithromycin may increase the QTc-prolonging activities of Haloperidol."